Date | Price Target | Rating | Analyst |
---|---|---|---|
12/8/2023 | $3.00 | Buy | H.C. Wainwright |
9/25/2023 | $3.50 → $2.00 | Buy → Hold | Canaccord Genuity |
10/20/2021 | $13.00 | Buy | Canaccord Genuity |
Quantum-Si Incorporated (NASDAQ:QSI) ("Quantum-Si," "QSI" or the "Company"), The Protein Sequencing Company™, today announced a presentation by Gloria Sheynkman, Ph.D., Assistant Professor in the Department of Molecular Physiology and Biological Physics at the University of Virginia at the Festival of Genomics and Biodata conference being held in Boston on June 12-13, 2024.The presentation, titled "Next Generation Proteomics to Detect Disease-Relevant Proteoforms" will be on Wednesday, June 12th at 2:50 p.m. on the Omics Stage and will describe the application of Quantum-Si's Next-Generation Protein Sequencing ("NGPS") to identify protein variants that have a role in complex disease.
Quantum-Si Incorporated (NASDAQ:QSI) ("Quantum-Si," "QSI" or the "Company"), The Protein Sequencing Company™, today announced the appointment of Charles ("Chuck") Kummeth to the role of independent Chairman of the Board, effective May 27, 2024.Mr. Kummeth has over 35 years of leadership experience in Life Sciences most recently as President and CEO of Bio-Techne. During Mr. Kummeth's tenure at Bio-Techne, he oversaw tremendous growth across all aspects of the business including annual revenue growth from $300M to over $1.1B, growth in the employee base from 800 to over 3,000, and the successful execution of 19 acquisitions, all while maintaining a 35% or better EBITDA level. Under Mr. Kummet
HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Quantum-Si (NASDAQ:QSI) with a Buy and maintains $4 price target.
Quantum-Si Incorporated (NASDAQ:QSI) ("Quantum-Si," "QSI" or the "Company"), The Protein Sequencing Company™, today announced that Liberate Bio, a Boston-based biotech unleashing the potential of genetic medicines with novel delivery vehicles, has integrated the Platinum® Next-Generation Protein Sequencer™ ("NGPS") into their platform for developing novel gene therapies with improved targeting capabilities. Liberate is using the sequencer's protein barcoding application to screen lipid nanoparticle delivery vehicles in vivo, with a simple readout of delivery and translation efficiency, dramatically increasing the precision, speed, and efficiency of their gene therapy discovery and developme
Quantum-Si Incorporated (NASDAQ:QSI) ("Quantum-Si," "QSI" or the "Company"), The Protein Sequencing Company™, today announced that Todd Bennett will join QSI as the Company's new Chief Commercial Officer effective September 16, 2024, John Vieceli, Ph.D. has been named Chief Product Officer and Lindsay Thompson has been named Chief Human Resources Officer. "I am pleased to welcome Todd to QSI as we look to leverage his breadth of industry experience to accelerate the global adoption of Platinum®. Todd is a highly regarded commercial leader in our industry and his track record of building high performing commercial teams and driving market adoption of new technologies is perfectly aligned w
Quantum-Si Incorporated (NASDAQ:QSI) ("Quantum-Si," "QSI" or the "Company"), The Protein Sequencing CompanyTM, today announced that it will be participating in the 26th Annual H.C. Wainwright Global Investment Conference taking place in New York City September 9-11, 2024. Jeff Hawkins, Quantum-Si's Chief Executive Officer, will participate in a fireside chat on Tuesday, September 10th, at 4:00 PM ET. A live and archived webcast of the event will be available in the "Investors" section of the Quantum-Si website under Events & Presentations. About Quantum-Si Incorporated Quantum-Si, The Protein Sequencing Company™, is focused on revolutionizing the growing field of proteomics. The Compa
H.C. Wainwright initiated coverage of Quantum-Si with a rating of Buy and set a new price target of $3.00
Canaccord Genuity downgraded Quantum-Si from Buy to Hold and set a new price target of $2.00 from $3.50 previously
Canaccord Genuity initiated coverage of Quantum-Si with a rating of Buy and set a new price target of $13.00
4 - Quantum-Si Inc (0001816431) (Issuer)
3 - Quantum-Si Inc (0001816431) (Issuer)
4 - Quantum-Si Inc (0001816431) (Issuer)
4 - Quantum-Si Inc (0001816431) (Issuer)
4 - Quantum-Si Inc (0001816431) (Issuer)
4 - Quantum-Si Inc (0001816431) (Issuer)
Announces Release of Version 3 Sequencing Kit Announces Two Additional Kit Launches Expected by End of 2024 Quantum-Si Incorporated (NASDAQ:QSI) ("Quantum-Si," "QSI" or the "Company"), The Protein Sequencing Company™, today announced financial results for the second quarter ended June 30, 2024. Press Release Highlights Reported revenue of $622,000 in the second quarter of 2024 Completed the first quarter of full commercial launch of the Platinum® instrument in Q2 2024 Announces the launch of the version 3 sequencing kit Announced appointment of Chuck Kummeth as independent Chairman of the Board of Directors Expect to l
Quantum-Si Incorporated (NASDAQ:QSI) ("Quantum-Si," "QSI" or the "Company"), The Protein Sequencing CompanyTM, today announced that it will report financial results for the second quarter of 2024 on Wednesday, August 7, 2024. Company management will host a conference call to discuss financial results and provide a business update on the same day at 4:30 PM ET. Individuals interested in listening to the conference call may do so by joining the live webcast on the Investors section of the Quantum-Si website under Events and Presentations. Alternatively, individuals can register here to receive a dial-in number and personalized PIN to participate in the call. An archived webcast of the eve
Executed Full Commercial Launch of Platinum® Instrument Reaffirms Full Year 2024 Financial Guidance Quantum-Si Incorporated (NASDAQ:QSI) ("Quantum-Si," "QSI" or the "Company"), The Protein Sequencing Company™, today announced financial results for the first quarter ended March 31, 2024. Press Release Highlights Reported revenue of $457,000 in the first quarter of 2024 Commenced its full commercial launch of its Platinum® instrument at the end of March 2024 On track to launch version 3 of its sequencing kit, which is expected by the end of Q3 2024 Announced addition of Paula Dowdy to the Board of Directors Announced the release of a new version of Platinum® Analysis Soft
SC 13D/A - Quantum-Si Inc (0001816431) (Subject)
SC 13G/A - Quantum-Si Inc (0001816431) (Subject)
SC 13G - Quantum-Si Inc (0001816431) (Subject)
8-K - Quantum-Si Inc (0001816431) (Filer)
8-K - Quantum-Si Inc (0001816431) (Filer)
10-Q - Quantum-Si Inc (0001816431) (Filer)
Quantum-Si Incorporated (NASDAQ:QSI) ("Quantum-Si," "QSI" or the "Company"), The Protein Sequencing Company™, today announced the appointment of Charles ("Chuck") Kummeth to the role of independent Chairman of the Board, effective May 27, 2024. Mr. Kummeth has over 35 years of leadership experience in Life Sciences most recently as President and CEO of Bio-Techne. During Mr. Kummeth's tenure at Bio-Techne, he oversaw tremendous growth across all aspects of the business including annual revenue growth from $300M to over $1.1B, growth in the employee base from 800 to over 3,000, and the successful execution of 19 acquisitions, all while maintaining a 35% or better EBITDA level. Under Mr. Ku
Quantum-Si Incorporated (NASDAQ:QSI) ("Quantum-Si," "QSI" or the "Company"), The Protein Sequencing CompanyTM, today announced the appointment of Paula Dowdy, a senior executive with more than 35 years of experience across life sciences, enterprise software, and technology industries, to its Board of Directors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240321183506/en/Paula Dowdy (Photo: Business Wire) Ms. Dowdy currently serves on the Board of Directors for SPT Labtech, a world leading lab automation tools company based in the UK and is an advisor at EQT Life Sciences, one of Europe's leading investors targeting innovative
Quantum-Si Incorporated (NASDAQ:QSI) ("Quantum-Si," "QSI" or the "Company"), The Protein Sequencing Company™, today announced that it has entered into an agreement with a new distributor who will make the company's protein sequencing instrument, Platinum® available for the first time in Japan. TOMY Digital Biology Co., Ltd., a renowned importer and distributor with a rich history dating back to the 1950s, will distribute Quantum-Si's next-generation protein sequencer™ and associated consumables throughout Japan. "Working with Quantum-Si marks a pivotal moment for TOMY Digital Biology, aligning with our commitment to advancing life sciences. We're poised to empower Japanese researchers wit